Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America

References

• Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician’s guide to biosimilars in oncology. Cancer Treat Rev. 2016;46:73–79. doi:10.1016/j.ctrv.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Scheinberg M, Castañeda-Hernández G. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther. 2014;16(6):501. doi:10.1186/s13075-014-0501-5.
   PubMed Web of Science ®Google Scholar
• Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(1):63–68. doi:10.1093/gastro/gou087.
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostör AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260. doi:10.1136/pgmj.2006.052688.
   PubMed Web of Science ®Google Scholar
• Baer WH, Maini A, Jacobs I. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey. Pharmaceuticals (Basel). 2014;7(5):530–544. doi:10.3390/ph7050530.
   PubMedGoogle Scholar
• Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals (Basel). 2014;7(9):943–953. doi:10.3390/ph7090943.
   PubMedGoogle Scholar
• Monk BJ, Lammers PE, Cartwright T, Jacobs I. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. Pharmaceuticals (Basel). 2017;10(1):pii: E19. doi:10.3390/ph10010019.
   PubMedGoogle Scholar
• Ugarte-Gil MF, Silvestre AM, Pons-Estel BA. Access to an optimal treatment. Current situation. Clin Rheumatol. 2015;34(Suppl 1):S59–66. doi:10.1007/s10067-015-3018-7.
   PubMedGoogle Scholar
• Li E, Subramanian J, Anderson S, Thomas D, McKinley J, Jacobs IA. Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther. 2015;9:3247–3255. doi:10.2147/DDDT.S75219.
   PubMed Web of Science ®Google Scholar
• Chamberlain C, Collin SM, Stephens P, Donovan J, Bahl A, Hollingworth W. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales. Br J Cancer. 2014;111(9):1693–1702. doi:10.1038/bjc.2014.86.
   PubMed Web of Science ®Google Scholar
• Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683. doi:10.1371/journal.pone.0119683.
   PubMed Web of Science ®Google Scholar
• Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis–the Health Outcomes Patient Environment (HOPE) study. Rheumatol Int. 2014;34(1):25–33. doi:10.1007/s00296-013-2866-1.
   PubMed Web of Science ®Google Scholar
• Laires PA, Mesquita R, Veloso L, Martins AP, Cernadas R, Fonseca JE. Patient’s access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. BMC Musculoskelet Disord. 2013;14(1):279. doi:10.1186/1471-2474-14-279.
   PubMedGoogle Scholar
• Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015; 21(6):1728–1737. doi:10.3748/wjg.v21.i6.1728.
   PubMed Web of Science ®Google Scholar
• Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. J Oncol Pract. 2012;8(3):190–195. doi:10.1200/JOP.2011.000337.
   PubMedGoogle Scholar
• Jacobs I, Petersel D, Shane LG, Ng CK, Kirchhoff C, Finch G, Lula S. Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence. BioDrugs. 2016;30(6):489–523. doi:10.1007/s40259-016-0199-9.
   PubMed Web of Science ®Google Scholar
• IMS Health. The impact of biosimilar competition. 2016 Jun [ accessed 2017 Apr 6]. http://ec.europa.eu/DocsRoom/documents/17325/attachments/1/translations/en/renditions/native.
   Google Scholar
• Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PE, Soto-Perez-de-Celis E, Dizon D, Cazap E, de Lima Lopes G Jr., et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. 2015; 16(14):1405–1438. doi:10.1016/S1470-2045(15)00218-1.
   PubMed Web of Science ®Google Scholar
• Al Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester GR, Cutolo M, Flood J, March L, McDonald-Blumer H, Pile K, et al. The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol. 2015; 34(5):819–829. doi:10.1007/s10067-014-2841-6.
   PubMed Web of Science ®Google Scholar
• Ruiz R, Strasser-Weippl K, Touya D, Herrero Vincent C, Hernandez-Blanquisett A, St Louis J, Bukowski A, Goss PE. Improving access to high-cost cancer drugs in Latin America: much to be done. Cancer. 2017;123(8):1313–1323. doi:10.1002/cncr.30549.
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Health in the Americas, 2012 edition: regional Volume. Chapter 5. Health Systems and Social Protection in Health. 2012 [ accessed 2017 Apr 6]. http://www.paho.org/saludenlasamericas/index.php?option=com_docman&task=doc_view&gid=166&Itemid=.
   Google Scholar
• Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin. 2013;9(2):106–112. doi:10.1016/j.reuma.2012.09.001.
   PubMedGoogle Scholar
• Chouela E, Amaya M, Londoño A, Romiti R, Valenzuela F, Duarte AA, Perez Alfonzo R, Borlenghi C. Psoriasis in Latin America. Dermatol Online J. 2016;22(9):pii:13030/qt4wn3m8xt.
   PubMedGoogle Scholar
• Debiasi M, Reinert T, Kaliks R, Amorim G, Caleffi M, Sampaio C, Fernandes GDS, Barrios CH. Estimation of premature deaths from lack of access to anti-HER2 therapy for advanced breast cancer in the Brazilian public health system. J Glob Oncol. 2017;3(3):201–207. doi:10.1200/JGO.2016.005678.
   PubMed Web of Science ®Google Scholar
• Debiasi M, Pimentel FF, Pereira PJS, Barrios CH. Biosimilars in Brazil: the beginning of an era of broader access. J Cancer Ther. 2017;08(09):814–826. doi:10.4236/jct.2017.89071.
   Google Scholar
• Biehl J, Petryna A, Gertner A, Amon JJ, Picon PD. Judicialisation of the right to health in Brazil. Lancet. 2009;373(9682):2182–2184. doi:10.1016/S0140-6736(09)61172-7.
   PubMed Web of Science ®Google Scholar
• Tobar F, Charreau J. Comparación internacional del precio de los medicamentos de alto costo Argentina, Países del Cono sur, España e Italia Instituto de Estudios Sobre Políticas de Salud. 2011 Dec 28 [ accessed 2018 Mar 22]. http://www.aapmra.com/informes/11-12-28_Medicamentos-de-Alto-Costo-Acceso-y-Politicas.pdf.
   Google Scholar
• Gewanter HL, Reilly MS. Prescribing practices for biosimilars: questionnaire survey findings from physicians in Argentina, Brazil, Colombia and Mexico. Generics Biosimilars Initiat J. 2015;4(4):161–166. doi:10.5639/gabij.2015.0404.036.
   Google Scholar
• Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, et al. Biosimilars: what clinicians should know. Blood. 2012; 120(26):5111–5117. doi:10.1182/blood-2012-04-425744.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). 2009 [ accessed 2017 Apr 6]. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf.
   Google Scholar
• US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015 Apr [accessed 2017 Apr 6]. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products. 2014 Oct 23 [accessed 2017 Apr 6]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
   Google Scholar
• Health Canada. Guidance document: information and submission requirements for biosimilar biologic drugs. 2016 Nov 14 [accessed 2017 Apr 6]. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2016-eng.pdf.
   Google Scholar
• Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima. mAbs. 2014;6(5):1163–1177. doi:10.4161/mabs.32221.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Inflectra. 2013 Jun 27 [ accessed 2017 Apr 6]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf.
   Google Scholar
• European Medicines Agency. Assessment report. Remsima. 2013 Jun 27 [ accessed 2017 Apr 6]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf.
   Google Scholar
• Celltrion. CT-P13 FDA advisory committee briefing document. 2016 Feb 9 [ accessed 2017 Mar 27]. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484860.pdf.
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012 May [accessed 2017 Apr 27]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf.
   Google Scholar
• Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196. doi:10.1182/blood-2014-06-583617.
   PubMed Web of Science ®Google Scholar
• Schellekens H, Lietzan E, Faccin F, Venema J. Biosimilar monoclonal antibodies: the scientific basis for extrapolation. Expert Opin Biol Ther. 2015;15(11):1633–1646. doi:10.1517/14712598.2015.1083552.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry. 2016 Dec [ accessed 2017 Apr 6]. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf.
   Google Scholar
• US Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. 2015 Apr [ accessed Apr 6]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
   Google Scholar
• International Federation of Pharmaceutical Manufacturers & Associations. Policy statement. Non-comparable biotherapeutic products. 2014 July 24 [accessed 2017 Oct 24]. https://www.ifpma.org/wp-content/uploads/2016/02/Non-comparable_Biotherapeutic_Products__English__02.pdf.
   Google Scholar
• Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, Jacobs I. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36(5):613–625. doi:10.1007/s00296-016-3444-0.
   PubMed Web of Science ®Google Scholar
• Álvarez AA, Mysler E, Ruiz De Castilla EM, Flores-Murrieta FJ, Hughes J, Azevedo VF. Recommendations for the regulation of biosimilars and their implementation in Latin America. Generics Biosimilars Initiat J. 2014;3(3):143–148. doi:10.5639/gabij.2014.0303.032.
   Google Scholar
• Garcia R, Araujo DV. The regulation of biosimilars in Latin America. Curr Rheumatol Rep. 2016;18(3):16. doi:10.1007/s11926-016-0564-1.
   PubMed Web of Science ®Google Scholar
• Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya J-M. Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars. 2013;3:1–17. doi:10.2147/bs.s38572.
   Google Scholar
• Babini A, Age Kos I, Matar P, Teixeira FV, Azevedo VF. New monoclonal antibody biosimilars approved in 2015 in Latin America: position statement of the Latin American Forum on Biosimilars in biosimilarity, interchangeability and extrapolation of indications. Generics Biosimilars Initiat J. 2016;5(2):66–69. doi:10.5639/gabij.2016.0502.017.
   Google Scholar
• de la Cruz C, De Carvalho AV, Dorantes GL, Londoño Garcia AM, Gonzalez C, Maskin M, Podoswa N, Redfern JS, Valenzuela F, van der Walt J, et al. Biosimilars in psoriasis: clinical practice and regulatory perspectives in Latin America. J Dermatol. 2017; 44(1):3–12. doi:10.1111/1346-8138.13512.
   PubMed Web of Science ®Google Scholar
• Castañeda-Hernández G, Szekanecz Z, Mysler E, Azevedo VF, Guzman R, Gutierrez M, Rodríguez W, Karateev D. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine. 2014;81(6):471–477. doi:10.1016/j.jbspin.2014.03.019.
   PubMed Web of Science ®Google Scholar
• Ministro de Salud y Protección Social. Decreto número 1782 de 2014. 2014 Sep 18 [accessed 2018 Mar 26]. https://www.minsalud.gov.co/Normatividad_Nuevo/Decreto%201782%20de%202014.pdf.
   Google Scholar
• Damond J. BIO WTO Comments on Colombia’s Proposed Biologics and Biosimilars Regulations. 2013 Oct 4 [accessed 2017 Jan 3]. https://www.bio.org/sites/default/files/files/BIO%20WTO%20Comments_Colombia%20Proposed%20Biologics%20%26%20Biosimilars%20Regulations.pdf
   Google Scholar
• Lietzan E. How Colombia’s biosimilar regulation departs from international norms. Rev Panam Salud Publica. 41;2018:e78.
   PubMed Web of Science ®Google Scholar
• Gaviria A, Vaca González CP, Gómez Muñoz C, Morales AA. El debate de la regulación de medicamentos biotecnológicos: colombia en el contexto internacional. Rev Panam Salud Publica. 2016;40(1):40–47.
   PubMed Web of Science ®Google Scholar
• Vaca C, Gaviria A, Gomez C. Response regarding Colombian regulation of biotherapeutic products. Rev Panam Salud Publica. 41;2018:e129.
   PubMed Web of Science ®Google Scholar
• Mysler E, Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol. 2012;31(9):1279–1280. doi:10.1007/s10067-012-2068-3.
   PubMed Web of Science ®Google Scholar
• Castañeda-Hernández G, González-Ramírez R, Kay J, Scheinberg MA. Biosimilars in rheumatology: what the clinician should know. RMD Open. 2015;1(1):e000010. doi:10.1136/rmdopen-2014-000010.
   PubMed Web of Science ®Google Scholar
• Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology–“O brave new world”. Nat Rev Rheumatol. 2012;8(7):430–436. doi:10.1038/nrrheum.2012.84.
   PubMed Web of Science ®Google Scholar
• Tout M, Passot C, Cartron G, Paintaud G, Ternant D. Gota, et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab”. Cancer Chemother Pharmacol. 2016; 78(6):1317–1318. doi:10.1007/s00280-016-3176-6.
   PubMed Web of Science ®Google Scholar
• Scheinberg M. Is Etanar a new biologic? Clin Exp Rheumatol. 2016;34(5):954.
   PubMed Web of Science ®Google Scholar
• Hassett B, Scheinberg M, Castaneda-Hernandez G, Li M, Rao URK, Singh E, Mahgoub E, Coindreau J, O’Brien J, Vicik SM, et al. Variability of intended copies for etanercept (Enbrel®): data on multiple batches of seven products. MAbs. 2018; 10(1):166–176. doi:10.1080/19420862.2017.1387346.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. 2017 April 27 [accessed 2018 Mar 21]. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
   Google Scholar
• GaBI Online. Mexico issues rules on biolimbos. 2015 Mar 13 [accessed 2017 Apr 6]. http://www.gabionline.net/Guidelines/Mexico-issues-rules-on-biolimbos.
   Google Scholar
• World Health Organization. Regulatory assessment of approved rDNA-derived biotherapeutics, Technical Report Series, No. 999, Annex 3. 2016 [ accessed 2017 Apr 6]. http://www.who.int/biologicals/areas/biological_therapeutics/Annex_3_Regulatory_assessment_of_approved_rDNA-derived_biotherapeutics.pdf?ua=1.
   Google Scholar
• Jacobs I, Ewesuedo R, Lula S, Zacharchuk C. Biosimilars for the treatment of cancer: a systematic review of published evidence. BioDrugs. 2017;31(1):1–36. doi:10.1007/s40259-016-0207-0.
   PubMed Web of Science ®Google Scholar
• Administración Nacional de Medicamentos Alimentos y Tecnología Médica. Disposicion no. 7060. 2014 Oct 2 [accessed 2018 Mar 26]. http://www.anmat.gov.ar/boletin_anmat/Octubre_2014/Dispo_7060-14.pdf.
   Google Scholar
• Candelaria M, Gonzalez D, Beniwal S, Dasappa L, Bar D, Delamain M, Mukhopadhyay A, Flores D, Bhurani D, Radhakrishnan V, et al. A randomized, double-blind, phase III study comparing proposed biosimilar rituximab (RTXM83) versus reference rituximab, both in combination with CHOP, in the first line treatment of patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2017;130(Suppl 1):1556.
   Google Scholar
• Candelaria M, Gonzalez D, Fernandez Gomez FJ, Paravisini A, Del Campo Garcia A, Perez L, Miguel-Lillo B, Millan S. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol. 2018;81(3):515–527. doi:10.1007/s00280-018-3524-9.
   PubMed Web of Science ®Google Scholar
• Administración Nacional de Medicamentos Alimentos y Tecnología Médica. Disposicion no. 6069. 2016 Jun 6 [accessed 2017 Jan 4]. http://www.anmat.gov.ar/boletin_anmat/junio_2016/Dispo_6069-16.pdf.
   Google Scholar
• Administración Nacional de Medicamentos Alimentos y Tecnología Médica. Disposicion no. 11326. 2016 Oct 14 [ accessed 2017 Aug 21]. http://www.anmat.gov.ar/boletin_anmat/octubre_2016/Dispo_11326-16.pdf.
   Google Scholar
• Roca EL, Vinnyk Y, Bondarenko I, Shparyk YV, Bariani GM, Abdalla K, Franke F, Cruz F, Romera A, Bhamare S, et al. 2017. Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer. J Clin Oncol. 35(15_suppl):e14065–e.
   Google Scholar
• Biocad. BIOCAD registered the first rituximab biosimilar in Bolivia and Honduras. 2017 Jun 6 [accessed 2017 Aug 22]. http://biocadglobal.com/post/BIOCAD_registered_the_first_rituximab_biosimilar_in_Bolivia_and_Honduras.
   Google Scholar
• Eremeeva A, Chernyaeva E, Ivanov R, Nasonov E, Knyazeva L. FRI0224 Comparison of efficacy and safety of rituximab biosimilar, BCD-020, and innovator rituximab in patients with active rheumatoid arthritis refractory to TNFA inhibitors. Ann Rheum Dis. 2016;75(Suppl 2):513–514. doi:10.1136/annrheumdis-2016-eular.1715.
   Google Scholar
• GaBI Online. Rituximab non-originator biological approved in Russia. 2014 Apr 25 [accessed Mar 28]. http://www.gabionline.net/Biosimilars/News/Rituximab-non-originator-biological-approved-in-Russia.
   Google Scholar
• Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713–724. doi:10.1038/nrrheum.2015.110.
   PubMed Web of Science ®Google Scholar
• Celltrion. Celltrion brochure. 2017 Jun 30 [ accessed 2017 Sep 5]. https://www.celltrion.com/en/pr/brochure.do.
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72(10):1613–1620. doi:10.1136/annrheumdis-2012-203090.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013; 72(10):1605–1612. doi:10.1136/annrheumdis-2012-203091.
   PubMed Web of Science ®Google Scholar
• Teixeira FV, Kotze PG, Damião AO. Anvisa approves the first biosimilar monoclonal antibody based on comparability in Brazil. Arq Gastroenterol. 2016;53(2):60–61. doi:10.1590/S0004-28032016000200002.
   PubMedGoogle Scholar
• Agência Nacional de Vigilância Sanitária. Detalhe do Produto: Brenzys. 2018 Jan 19 [accessed 2018 Mar 20]. https://consultas.anvisa.gov.br/#/medicamentos/25351459382201601/?nomeProduto=brenzys.
   Google Scholar
• Agência Nacional de Vigilância Sanitária. Detalhe do Produto: Zedora. 2018 Feb 19 [accessed 2018 Mar 20]. https://consultas.anvisa.gov.br/#/medicamentos/25351595780201605/?nomeProduto=zedora.
   Google Scholar
• European Medicines Agency. Assessment report: Benepali. 2015 Nov 19 [accessed 2018 Mar 20]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf.
   Google Scholar
• US Food and Drug Administration. FDA briefing document. Oncologic drugs advisory committee meeting. July 13, 2017. BLA 761074. 2017 Jul 13 [accessed 2018 Mar 20]. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566369.pdf.
   Google Scholar
• Pineda C, Caballero-Uribe CV, de Oliveira MG, Lipszyc PS, Lopez JJ, Mataos Moreira MM, Azevedo VF. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol. 2015;34(4):635–640. doi:10.1007/s10067-015-2887-0.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European public assessment reports. [ accessed 2017 Apr 5]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• US Food and Drug Administration. FDA approves first biosimilar product Zarxio. 2015 Mar 06 [accessed 2018 Apr 5]. https://wayback.archive-it.org/7993/20170111224313/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm.
   Google Scholar
• Im YH, Odarchenko P, Grecea D, Komov D, Anatoliy CV, Gupta S, Shparyk YV, Caguioa PB, Makhson A, Krasnozhon D, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol. 2013;31(15 suppl):abstract 629.
   Google Scholar
• Isakov L, Jin B, Jacobs IA. Statistical primer on biosimilar clinical development. Am J Ther. 2016;23(6):e1903–e10. doi:10.1097/MJT.0000000000000391.
   PubMed Web of Science ®Google Scholar
• Amgen. FDA approves Amgen and Allergan’s MVASI™ (bevacizumab-awwb) for the treatment of five types of cancer. 2017 Sep 14 [accessed 2017 Sep 18]. http://www.amgen.com/media/news-releases/2017/09/fda-approves-amgen-and-allergans-mvasi-bevacizumabawwb-for-the-treatment-of-five-types-of-cancer/.
   Google Scholar
• Amgen. European Commission approves Amgen and Allergan’s MVASI® (biosimilar bevacizumab) for the treatment of certain types of cancer. 2018 Jan 18 [accessed 2018 Feb 1]. http://www.amgen.com/media/news-releases/2018/01/european-commission-approves-amgen-and-allergans-mvasi-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer/.
   Google Scholar
• Rioufol C, Salles G. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev Anticancer Ther. 2015;15(5):569–578. doi:10.1586/14737140.2015.1028919.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014; 15(4):424–435. doi:10.1016/S1470-2045(14)70027-0.
   PubMed Web of Science ®Google Scholar
• Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology (Oxford). 2017;56(2):187–197. doi:10.1093/rheumatology/kew206.
   PubMed Web of Science ®Google Scholar
• GaBI Online. Australia approves rituximab biosimilar Truxima. 2018 Apr 27 [accessed 2018 Apr 30]. http://www.gabionline.net/Biosimilars/News/Australia-approves-rituximab-biosimilar-Truxima.
   Google Scholar
• Celltrion Healthcare Hungary Kft. Truxima. Summary of product characteristics. 2017 Mar 8 [accessed 2017 Mar 15]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.
   Google Scholar
• European Medicines Agency. Assessment report. Truxima. 2016 Dec 15 [accessed 2017 Apr 6]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004112/WC500222695.pdf.
   Google Scholar
• Yoo DH, Suh CH, Shim SC, Jeka S, Cons-Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017; 76(3):566–570. doi:10.1136/annrheumdis-2016-209540.
   PubMed Web of Science ®Google Scholar
• Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JA, Prokharau A, Vasilica M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017; 4(8):e362–e73. doi:10.1016/S2352-3026(17)30120-5.
   PubMed Web of Science ®Google Scholar
• Chan-Ok S, Kim M. Celltrion to launch Truxima in Colombia, stretch to other Latin American markets. 2018 Feb 21 [accessed 2018 Mar 21]. http://pulsenews.co.kr/view.php?year=2018&no=119701
   Google Scholar
• Sandoz. Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases. 2017 Jun 19 [accessed 2017 Aug 21]. https://www.sandoz.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood.
   Google Scholar
• Therapeutic Goods Administration. Prescription medicines and biologicals: TGA annual summary 2017. 2018 Jan [ accessed 2018 Mar 21]. https://www.tga.gov.au/sites/default/files/prescription-medicines-and-biologicals-tga-annual-summary-2017.pdf.
   Google Scholar
• Curigliano G, O’Connor DP, Rosenberg JA, Jacobs I. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016;104:131–137. doi:10.1016/j.critrevonc.2016.06.002.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii D, Pikiel J, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017; 18(7):917–928. doi:10.1016/S1470-2045(17)30434-5.
   PubMed Web of Science ®Google Scholar
• Celltrion. Celltrion receives EU approval for trastuzumab biosimilar. 2018 Feb 14 [accessed 2018 Mar 20]. http://www.celltrion.com/en/pr/reportDetail.do?seq=476.
   Google Scholar
• Nippon Kayaku Co Ltd. Nippon Kayaku receives manufacture and marketing approval in Japan for biosimilar of trastuzumab monoclonal antibody. 2018 Mar 23 [accessed 2018 Mar 26]. https://www.nipponkayaku.co.jp/english/news/detail.php?n=20180323_E2HVSD66.
   Google Scholar
• Samsung Bioepis. Pipeline. 2017 Dec [accessed 2018 Mar 20]. http://www.samsungbioepis.com/en/pipeline/.
   Google Scholar
• Mylan NV. US FDA approves Mylan and Biocon’s Ogivri™, the first biosimilar for trastuzumab, for the treatment of HER2-positive breast and gastric cancers. 2017 Dec 1 [accessed 2018 Mar 21]. http://newsroom.mylan.com/2017-12-01-U-S-FDA-Approves-Mylan-and-Biocons-Ogivri-TM-the-First-Biosimilar-for-Trastuzumab-for-the-Treatment-of-HER2-Positive-Breast-and-Gastric-Cancers.
   Google Scholar
• Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017; 317(1):37–47. doi:10.1001/jama.2016.18305.
   PubMed Web of Science ®Google Scholar
• Mylan NV. Biocon and Mylan’s biosimilar trastuzumab receives approval from ANVISA, Brazil through their partner Libbs. 2017 Dec 29 [accessed 2018 Feb 20]. http://newsroom.mylan.com/2017-12-29-Biocon-and-Mylans-Biosimilar-Trastuzumab-Receives-Approval-from-ANVISA-Brazil-Through-their-Partner-Libbs.
   Google Scholar
• Amgen. Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration. 2017 Jul 31 [accessed 2017 Aug 21]. http://www.amgen.com/media/news-releases/2017/07/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food-and-drug-administration/.
   Google Scholar
• Pfizer Inc. Pfizer presents positive pivotal data for PF-05280014, an investigational biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress. 2017 Sep 10 [accessed 2017 Sep 11]. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_positive_pivotal_data_for_pf_05280014_an_investigational_biosimilar_to_herceptin_trastuzumab_at_the_european_society_for_medical_oncology_esmo_2017_congress.
   Google Scholar
• Amgen. Amgen and Allergan receive positive CHMP opinion for ABP 980 (biosimilar Herceptin®) for the treatment of three types of cancer. 2018 Mar 23 [accessed 2018 Mar 26]. http://www.amgen.com/media/news-releases/2018/03/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the-treatment-of-three-types-of-cancer/.
   Google Scholar
• Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2016; 19(11):1157–1168. doi:10.1111/1756-185X.12711.
   PubMed Web of Science ®Google Scholar
• Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis. 2017;76(1):4–6. doi:10.1136/annrheumdis-2015-208113.
   PubMed Web of Science ®Google Scholar
• Kay J, Chopra A, Chandrashekara S, Olakkengil DJ, Bhojani KS, Bhatia G, Rathi G, Thomas M, Maroli S, Thomson ES, et al. OP0012 A phase 3, randomized, double-blind, active comparator study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2014; 73(Suppl 2):64. doi:10.1136/annrheumdis-2014-eular.1595.
   Google Scholar
• Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open. 2016;2(1):e000154. doi:10.1136/rmdopen-2015-000154.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. ABP 501. Summary review. 2016 Sep 23 [accessed 2017 Apr 5]. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM529946.pdf.
   Google Scholar
• Amgen. European Commission approves AMGEVITA™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases. 2017 Mar 23 [accessed 2017 Apr 5]. http://www.amgen.com/media/news-releases/2017/03/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases/.
   Google Scholar
• Boehringer Ingelheim. Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases. 2017 Nov 13 [accessed 2018 Mar 28]. https://www.boehringer-ingelheim.com/Marketing-Authorisation-granted-for-Cyltezo.
   Google Scholar
• Sandoz. Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency. 2017 May 31 [accessed 2017 Aug 21]. https://www.sandoz.com/news/media-releases/sandoz-proposed-biosimilars-adalimumab-and-infliximab-accepted-regulatory-review.
   Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017; 76(1):51–57. doi:10.1136/annrheumdis-2015-207588.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, Arenberger P, Pulka G, Kingo K, Weglowska J, Hattebuhr N, Poetzl J, Woehling H, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017; 176(4):928–938. doi:10.1111/bjd.15152.
   PubMed Web of Science ®Google Scholar
• Sandoz. Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases. 2017 Jun 27 [accessed 2017 Aug 21]. https://www.sandoz.com/news/media-releases/sandoz-receives-approval-europe-erelzir-biosimilar-etanercept-treat-multiple.
   Google Scholar
• Sandoz. Erelzi™ (etanercept), by Sandoz, is now available for patients in Canada for the treatment of multiple inflammatory diseases. 2017 Aug 21 [accessed 2017 Aug 21]. https://www.sandoz.ca/en/stories/medicines/erelzi-now-available.
   Google Scholar
• Sandoz. FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases. 2016 Aug 30 [ accessed 2017 Apr 6]. https://www.sandoz.com/news/media-releases/fda-approves-sandoz-erelzitm-treat-multiple-inflammatory-diseases.
   Google Scholar
• Samsung Bioepis. Samsung Bioepis’ Type II variation application for indication extension of Benepali® receives positive CHMP opinion. 2016 Dec 16 [accessed 2017 Apr 6]. http://www.samsungbioepis.com/en/newsroom/detail/Samsung-Bioepis-Type-II-Variation-Application-for-Indication-Extension-of-Benepali-Receives-Positive-CHMP-Opinion.html.
   Google Scholar
• Mochida Pharmaceutical Co Ltd. Mochida obtains marketing approval for etanercept biosimilar in Japan. 2018 Jan 19 [accessed 2018 Mar 20]. http://www.mochida.co.jp/english/news/docs/2018/180119_etanerceptBS.pdf.
   Google Scholar
• Lee H. LG Chem gets approval for Enbrel biosimilar. 2018 Mar 19 [accessed 2018 Mar 21]. http://www.koreabiomed.com/news/articleView.html?idxno=2816.
   Google Scholar
• Celltrion. FDA approves Celltrion’s Inflectra™ (infliximab-dyyb) for all eligible indications. 2016 Apr 22 [accessed 2017 Apr 6]. http://www.celltrion.com/en/pr/reportDetail.do?seq=329.
   Google Scholar
• Nichi-Iko Pharmaceutical Co Ltd. About marketing approval for Infliximab BS for I.V. infusion 100mg “Nichi-Iko” and the status of development in the U.S.A. 2017 Sep 27 [ accessed 2018 Mar 21]. http://www.nichiiko.co.jp/english/pdf/4541_20170927_01E.pdf.
   Google Scholar
• Pfizer Inc. FDA approves new Pfizer biosimilar. 2017 Dec 13 [ accessed 2018 Mar 21]. https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_new_pfizer_biosimilar.
   Google Scholar
• Samsung Bioepis. Samsung Bioepis obtains first drug approval in the United States, as the U.S. Food and Drug Administration approves RENFLEXIS™ (Infliximab-abda) across all eligible indications. 2017 Apr 24 [ accessed 2017 Aug 25]. http://www.samsungbioepis.com/en/newsroom/detail/Samsung-Bioepis-SB2-US-FDA-Approval-FINAL.html.
   Google Scholar
• Center for Drug Evaluation and Research. Inflectra summary review. 2016 Apr 5 [accessed 2017 Apr 5]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125544Orig1s000SumR.pdf.
   Google Scholar
• Teixeira FV, Kotze PG, Damião AO, Miszputen SJ. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists. Arq Gastroenterol. 2015;52(1):76–80. doi:10.1590/S0004-28032015000100016.
   PubMedGoogle Scholar
• Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45(8):1043–1057. doi:10.1111/apt.13990.
   PubMed Web of Science ®Google Scholar
• Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–589. doi:10.1016/j.crohns.2013.03.011.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017; 11(1):26–34. doi:10.1093/ecco-jcc/jjw198.
   PubMed Web of Science ®Google Scholar
• Moran N. Brazil aims to make biosimilars the foundation of its biotechnology sector. [ accessed 2017 Aug 21]. http://www.bioworld.com/content/brazil-aims-make-biosimilars-foundation-its-biotechnology-sector.
   Google Scholar
• Welch A. A Deep Dive Into Brazil’s Biosimilar PDPs. 2017 Jul 5 [accessed 2017 Aug 21]. https://www.biosimilardevelopment.com/doc/a-deep-dive-into-brazil-s-biosimilar-pdps-0001.
   Google Scholar
• Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, Lee YA, Smiyan S, Lim MJ, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017; 76(2):346–354. doi:10.1136/annrheumdis-2015-208783.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017; 76(2):355–363. doi:10.1136/annrheumdis-2015-208786.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, Lundin KEA, Mørk C, Jahnsen J, Kvien TK. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316. doi:10.1016/S0140-6736(17)30068-5.
   PubMed Web of Science ®Google Scholar
• Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016;18(8):50. doi:10.1007/s11926-016-0601-0.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, Meirelles Ede S, Kochen Jde A, Medeiros AC, Miszputen SJ, Teixeira FV, Damião AO, Kotze PG, Romiti R, Arnone M, et al. Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease–focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. Autoimmun Rev. 2015; 14(9):769–773. doi:10.1016/j.autrev.2015.04.014.
   PubMed Web of Science ®Google Scholar
• Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifoni MAC, Gil RA, Araujo DV. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Braz J Med Biol Res. 2018;51(3):e7214. doi:10.1590/1414-431X20177214.
   PubMed Web of Science ®Google Scholar
• Xibille D, Carrillo S, Huerta-Sil G, Hernandez R, Limon L, Olvera-Soto G, Jara-Quezada LJ, Esquivel A, Perez-Rodriguez M. Current state of biosimilars in Mexico: the position of the Mexican College of Rheumatology, 2016. Reumatol Clin. 2017. doi:10.1016/j.reuma.2017.07.002.
   Web of Science ®Google Scholar
• World Health Organization. Biological qualifier: an INN proposal. 2015 Oct [accessed 2017 Apr 6]. http://www.who.int/medicines/services/inn/WHO_INN_BQ_proposal_2015.pdf.
   Google Scholar
• Word Health Organization. Report on the expert consultation on improving access to and use of similar biotherapeutic products. 2017 Oct [accessed 2018 Mar 21]. http://www.who.int/medicines/access/biotherapeutics/FINAL_Report-improving-access-to-and-use-of-biotherapeutics_October2017.pdf.
   Google Scholar
• Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf. 2015;14(1):63–72. doi:10.1517/14740338.2015.972362.
   PubMed Web of Science ®Google Scholar
• Taylor P. Argentina extends medicine traceability initiative. 2012 Apr 5 [accessed 2017 Apr 6]. https://www.securingindustry.com/pharmaceuticals/argentina-extends-medicine-traceability-initiative/s40/a1214/#.WFPQoFWLSUl.
   Google Scholar
• Taylor P. May start for Brazil medicines traceability pilot. 2018 Jan 2 [accessed 2018 Mar 21]. https://www.securingindustry.com/pharmaceuticals/may-start-for-brazil-medicines-traceability-pilot/s40/a6578/#.WrOt1C7FKUk.
   Google Scholar
• US Food and Drug Administration. Prescribing biosimilar and interchangeable products. 2017 Oct 23 [accessed 2018 Apr 5]. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580430.htm.
   Google Scholar
• Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17(1):e31–8. doi:10.1016/S1470-2045(15)00381-2.
   PubMed Web of Science ®Google Scholar
• Rivera VM, Macias MA. Access and barriers to MS care in Latin America. Mult Scler J Exp Transl Clin. 2017;3(1):2055217317700668. doi:10.1177/2055217317700668.
   Google Scholar
• Larkin H, Macdonald J, Lumsden R. Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies. Generics Biosimilars Initiat J. 2017;6(4):157–164. doi:10.5639/gabij.2017.0604.034.
   Google Scholar